Clinical Trial

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Study acronym: iSPASM-2
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Trial Details
NCT Number NCT07493577
Lead Sponsor Dr David Hasan, M.D.
Collaborators: National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Aneurysmal Subarachnoid Hemorrhage
Enrollment 82 participants
Start Date 2026-07-23
Primary Completion 2029-01-23 (estimated)
Study Completion 2032-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-25